Fabre M, Lamoureux A, Meunier L, Samaran Q, et al. Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey. Melanoma Res 2024 Mar 28. doi: 10.1097/CMR.0000000000000963.
PMID: 38546723